By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today announced revenues of $345,000 for the fourth quarter and $1.2 million for full-year 2010, the first year that its OVA1 triage test for ovarian cancer was commercially available.

For the three months ended Dec. 31, 2010, the Austin, Texas-based molecular diagnostics company posted revenues of $345,000, compared to no revenues a year ago. Wall Street had expected $660,000 for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.